Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26999736 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2PIK3CAPIK3CBGAAEPHX1 | |
| SCHEMBL4648895 | 0.82 | TDP1 (0.36) | SMN1; SMN2GBA1 | |
| SCHEMBL5076199 | 0.82 | TDP1 (0.36) | SMN1; SMN2GBA1 | |
| SCHEMBL4895931 | 0.82 | TDP1 (0.36) | SMN1; SMN2GBA1 | |
| SCHEMBL204261 | 0.82 | TDP1 (0.36) | SMN1; SMN2GBA1 | |
| SCHEMBL17795772 | 0.82 | TDP1 (0.36) | SMN1; SMN2GBA1 | |
| SCHEMBL21515903 | 0.80 | GBA1 (0.31) | GBA1 | |
| SCHEMBL21514826 | 0.80 | GBA1 (0.31) | GBA1 | |
| SCHEMBL10076954 | 0.80 | GBA1 (0.31) | GBA1 | |
| Hydrochloric Acid SCHEMBL143429 | 0.80 | TDP1 (0.39) | SMN1; SMN2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083606-B1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA LP (US) | 2020-10-28 | — | — | EP | disclosed |
| US-9745287-B2 | Pyrimidines and use thereof | PURDUE PHARMA L.P. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160332992-A1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. | 2016-11-17 | — | — | US | disclosed |
| WO-2015094443-A1 | PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332992-A1 | PYRIMIDINES AND USE THEREOF | ADORA2B, P2RX2, P2RX3 | SMN1; SMN2 252/4885PIK3CA 2619/4885PIK3CB 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.